New COP Allergy Vaccine for Patients Allergic to Ragweed Pollen
Anergis develops a COP allergy vaccine for patients with moderate to severe allergy to ragweed pollen.
Ragweed pollen is extremely allergenic; it is believed to be the most allergenic of all pollens. Allergy to ragweed pollen is mostly present in the USA, where it affects 27 million patients, with a high degree of severity in many of them. Fifty percent (50%) of allergic patients in United States are sensitized to ragweed.
· Several reports indicate that the prevalence of ragweed allergies is rapidly increasing in Europe and has already reached high prevalence rates (Burbach et al. 2009, The Gatlen Network).
· Ragweed allergies are a major cause of asthma. In a survey by Burbach et al, 2009, 23.7% of all ambrosia-sensitized patients presented asthma symptoms.
The COP allergy vacine against ragweed pollen allergy is currently in preclinical development.